

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Abiomed, Inc. and Abiomed R&D, Inc.
Petitioner

v.

Maquet Cardiovascular, LLC
Patent Owner

Case No. IPR2017-1208

PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,597,437

CLAIMS 7-9, 11-15

TABLE OF CONTENTS

I. Introduction.....1

II. Mandatory Notices.....1

 A. Real Party-in-Interest1

 B. Related Matters1

 C. Counsel.....1

 D. Service Information.....2

III. Grounds for Standing.....2

IV. Relief Requested.....2

 A. The Challenged Claims Are Invalid in View of the Following Prior Art:2

 B. Grounds for Challenge3

V. The Challenged Claims Recited Nothing more than Conventional
Technology.....4

 A. Conventional Intravascular Blood Pumps and Use and Installation of
 Intravascular Blood Pumps.....4

 B. Conventional Techniques for Placing Intravascular Pumps5

 1. Over-the-Wire.....5

 2. Rapid-Exchange6

 3. Guide Catheter.....7

4.	Interchangeability of Over-the-Wire and Rapid-Exchange	7
VI.	Overview of the '437 Patent.....	8
A.	Summary of Alleged '437 Patent Invention	8
B.	No Patentable Synergy	12
C.	The Earliest Possible Priority Date is September 1, 2000	13
VII.	Overview of the Prior Art.....	14
A.	Overview of Aboul-Hosn.....	14
B.	Overview of Jegaden.....	20
C.	Overview of Yock.....	21
D.	Overview of Siess.....	22
E.	Overview of Wampler.....	22
VIII.	Claim construction.....	23
A.	“Distal”	24
B.	“Proximal”	25
IX.	Person having ordinary skill in the art.....	26
X.	Specific Grounds for Petition	26
A.	Ground I: Claims 7-9, and 11-15 are obvious in over Aboul-Hosn in view of Jegaden, and further in view of Siess and Wampler	27
1.	Claim 1 (Claims 7-9, 11-15 all depend from Claim 1)	27
2.	Claim 7	65

3. Claim 8	66
4. Claim 9	69
5. Claim 11	69
6. Claim 12	73
7. Claim 13	74
8. Claim 14	77
9. Claim 15	78
B. Ground II: Claims 7-9, and 11-15 are over Aboul-Hosn in view of Yock, and further in view of Siess and Wampler.....80	
1. Claim 1 (Claims 7-9 and 11-15 depend from Claim 1)	80
2. Claim 7	95
3. Claims 8, 9, 11-15	97
XI. Conclusion	97

TABLE OF AUTHORITIES

Page(s)

CASES

Dynamic Drinkware, LLC. v. Nat’l Graphics, Inc., 800 F.3d 1375
(Fed. Cir. 2015).....13

In re ICON Health & Fitness, Inc., 496 F.3d 1374 (Fed. Cir. 2007)24

STATUTES AND RULES

35 U.S.C. § 102(a)14

35 U.S.C. § 102(b)2, 3, 14

35 U.S.C. § 103(a)4

35 U.S.C. § 112 ¶ 114, 17, 19

35 U.S.C. § 312.....v

MISCELLANEOUS

37 C.F.R. § 42.8(b)(4).....2

37 C.F.R. § 42.24(a)(1).....iv

37 C.F.R. § 42.100(b)24

37 C.F.R. § 42.104v

37 C.F.R. § 42.24(d)iv

I. INTRODUCTION

Petitioner Abiomed, Inc. and Abiomed R&D, Inc. (collectively, “Petitioner”) petitions for *inter partes* review (“IPR”) of claims 7-9, 11-15 (the “Challenged Claims”) of U.S. Patent No. 9,975,437 (the “’437 patent”). The Challenged Claims add nothing new to the art and should be found unpatentable and canceled.

II. MANDATORY NOTICES

A. Real Party-in-Interest

The real parties in interest are Abiomed, Inc. and Abiomed R&D, Inc.

B. Related Matters

Petitioner has filed, or will file, concurrently with the present Petition: (1) petitions for IPR of claims 1-5, 10, 16, 18-29 of the ’437 patent; (2) petitions for IPR of U.S. Patent Nos. 9,561,314 and 9,545,468; and (3) petitions for IPR of U.S. Patent Nos. 7,022,100 (IPR2017-01025), 8,888,728 (IPR2017-01026 and IPR2017-01027), and 9,327,068 (IPR2017-01028 and IPR2017-01029) (the “related patents”) which are related to the ’437 patent.

C. Counsel

Lead Counsel: David M. Tennant (Reg. No. 48,362)

Backup Counsel: Charles D. Larsen (Reg. No. 48,533); Christopher Carroll (Reg. No. 55,776)

D. Service Information

Pursuant to 37 C.F.R. § 42.8(b)(4), papers concerning this matter should be served on the following. Petitioner consents to electronic service.

David M. Tennant (Reg. No. 48,362)

E-mail: WCAbiomedIPR@whitecase.com

Post and hand delivery: White & Case LLP

701 Thirteenth Street, NW

Washington, DC 20005

Telephone: (202) 626-3684

Fax: (202) 639-9355

III. GROUNDS FOR STANDING

Petitioner certifies the '437 patent is available for IPR and that Petitioner is not barred or estopped from requesting IPR of the Challenged Claims.

IV. RELIEF REQUESTED

Petitioner requests review of the Challenged Claims and a ruling that the Challenged Claims are unpatentable.

A. The Challenged Claims Are Invalid in View of the Following Prior Art¹:

1. WO99/02204 to Aboul-Hosn (EX1004, "Aboul-Hosn"), published January 21, 1999, is prior art under 35 U.S.C. § 102(b).

¹ The pre-AIA statutory framework applies.

2. U.S. Patent No. 5,921,913 to Siess (EX1005, “Siess”), filed June 24, 1997 and issued July 13, 1999, is prior art under 35 U.S.C. § 102(b).
3. Jegaden, Clinical results of Hemopump support in surgical cases, published in Temporary Cardiac Assist with an Axial Pump System, p.61-65 (Springer 1991) (EX1033, “Jegaden”), is prior art under 35 U.S.C. § 102(b).²
4. U.S. Patent No. 5,061,273 to Yock (EX1006, “Yock”), filed June 1, 1989 and issued October 29, 1991, is prior art under 35 U.S.C. § 102(b).
5. Wampler et al., Clinical Experience with the Hemopump Left Ventricular Support Device, published in Supported Complex and High Risk Coronary Angioplasty, ch. 14, 231-49 (Springer 1st ed. 1991) (EX1007, “Wampler”)in 1991, is prior art under 35 U.S.C. § 102(b).³

B. Grounds for Challenge

Petitioner respectfully requests review of the Challenged Claims and cancellation of those claims under the following statutory grounds:

² Jegaden bears a copyright date of 1991 and was publicly available from 1992.

See EX1033; Declaration of Susanne Leupold (EX1046).

³ Wampler bears a copyright date of 1991 and was publicly available from 1991.

See EX1007; Declaration of Kiersten Batzli (EX1035); Library of Congress Card Catalog (EX1036).

1. Claims 7-9, 11-15 are rendered obvious by Aboul-Hosn in view of Jegaden, and further in view of Siess and Wampler under 35 U.S.C. § 103(a).
2. Claims 7-9, 11-15 are rendered obvious by Aboul-Hosn in view of Yock, and further in view of Siess and Wampler under 35 U.S.C. § 103(a).

V. THE CHALLENGED CLAIMS RECITED NOTHING MORE THAN CONVENTIONAL TECHNOLOGY

A. Conventional Intravascular Blood Pumps⁴ and Use and Installation of Intravascular Blood Pumps

The features of the Challenged Claims were well known and included methods of providing left-heart support using an intravascular blood pump system using a cannula connected to an axial flow pump (Collins ¶¶52, 56-59), pumping blood axially along the pump and through the cannula (Collins ¶¶61-65), passing purge fluid to the intravascular blood pump through a catheter connected to the pump (Collins ¶¶66-72), and measuring blood pressure near the pump (Collins ¶¶73-79). The few other remaining details of the Challenged Claims were also well-known in the prior art. (Collins ¶¶102-10.)


⁴ For background, Dr. Collins discusses the circulatory anatomy and function, and development of intravascular blood pumps. (Collins ¶¶40-52.)

B. Conventional Techniques for Placing Intravascular Pumps

The guide wire mechanism of the Challenged Claims was also well-known in catheterization as the “rapid-exchange” technique. Along with “over-the-wire” and “guide catheters,” rapid-exchange was used routinely to position blood pumps intravascularly. (Collins ¶¶80-81.)

1. Over-the-Wire


POSITAs used “over-the-wire” guide mechanisms to place intravascular blood pumps. (Collins ¶85.) For example, Voelker FIG. 3 applied the “over-the-wire” guide mechanism to an axial flow intravascular blood pump with the guide wire extending through the shaft 19 and other components so that the pump may be slipped over the guide wire. (Collins ¶87; EX1011[Voelker] 3:56-60, FIG. 3).



(Collins ¶87; EX1011[Voelker] FIG. 3, annotated.)


2. Rapid-Exchange

Yock placed a conventional “rapid-exchange” catheter, a well-known catheterization technique, by sliding it along a guide wire extending through a sleeve secured to the exterior of the cannula or embedded within the cannula wall itself. (Collins ¶¶89-90; EX1006[Yock] FIG. 10, 7:64-8:2.)



(Collins ¶90; EX1006[Yock] FIG. 10, annotated.)

Voelker, at FIG. 2 (below) applied this rapid exchange approach as applied to an intravascular blood pump -- a guide wire 25 extended through a side channel 26 of a pump for positioning the pump as illustrated below. (Collins ¶92; EX1011[Voelker] 3:34-43.)



(Collins ¶92; EX1011[Voelker] FIG. 2, annotated.)

3. Guide Catheter

Yock also disclosed using a guide catheter to position a guide wire. (Collins ¶82; EX1006[Yock] 3:56-4:50.) The same technique has also been adapted to place axial flow intravascular blood pumps. (Collins ¶83), as acknowledged by the '437 Patent. (EX1001['437 Patent] 2:36-56.)

4. Interchangeability of Over-the-Wire and Rapid-Exchange

Over-the-wire and rapid-exchange techniques have long been used interchangeably, with minimal differences in design, to deliver cardiac assist devices, including blood pumps. (Collins ¶95; EX1023[Faxon] 58-59; EX1006[Yock] 8:16-25; EX1011[Voelker] FIGS. 2 and 3.) Over-the-wire and rapid-exchange were part of a limited set of delivery techniques. (Collins ¶96.) For example, U.S. Patent No. 5,928,181 to Coleman et al. (EX1042[Coleman])

discloses that catheters coupled to a cardiopulmonary bypass pump may be suitably guided into position using either technique. (EX1042[Coleman] 34:14-39.)

The interchangeability of over-the-wire and rapid-exchange was also well understood for intravascular blood pump applications. (Collins ¶97.) For example, Voelker’s blood pump could be configured to use either technique. (*Id.*; EX1011[Voelker] FIG. 2 (over-the-wire), and FIG. 3 (rapid-exchange).) Of course, deploying an intravascular blood pump to use over-the-wire or rapid-exchange involves certain design choices, but such design choices were also well-known within the prior art. (Collins ¶98; EX1001[Voelker] 3:34-55.)


There were a number of known advantages to using rapid-exchange compared to over-the wire, including a simplified exchange procedure, increased insertion speed, additional design flexibility. (Collins ¶¶99-100.)

VI. OVERVIEW OF THE ’437 PATENT

A. Summary of Alleged ’437 Patent Invention

The ’437 patent openly admits that it is not the first to use “guide mechanism[s]” to place an intravascular pump. (EX1001[’437 patent] 2:36-46.)

FIG. 1 of the ’437 patent illustrates a conventional over-the-wire placement technique. (*Id.* 5:25-30.)




(Collins ¶114; EX1001[’437 patent] FIG. 1, annotated.)

The conventional intravascular blood pump system includes an intravascular blood pump 12 rotor hub, cannula 14, and over-the-wire guide mechanism 16 with a guide wire lumen that passes through the center of the rotor hub and the cannula 14. (*Id.* 9:13-24; Collins ¶114.) The blood pump 12 provides heart support in the same manner as conventional axial-flow intravascular blood pumps – by “deliberately re-rout[ing] through and past the right and/or left ventricle in an

effort to reduce the volume of blood to be pumped by the particular ventricle.”

(*C.f.* EX1001[’437 patent] 20:43-48 *with id.* 2:16-19; Collins ¶114.)

FIG. 6 shows the conventional “rapid-exchange” or “side-rigger” guide mechanism of the prior art. (*Id.* 5:47-52.) The guide mechanism 122 “includes a guide carriage 124 formed along at least a portion of the cannula 14, and a suitable guide element (such as guide wire 22) dimensioned to pass slideably through a lumen (not shown) extending through the guide carriage 124.” (*Id.* 14:15-21; Collins ¶116-117)



(Collins ¶117; EX1001['437 patent] FIG. 6, annotated.)

Finally, the '437 patent at FIG. 10 shows a "guide catheter" mechanism 132 as in the prior art, with the rotor and shroud delivered – two separate steps.

(EX1001['437 patent] 5:65-6:3; Collins ¶119.)

elements and that were well-known as of the earliest priority date, starting with the Hemopump years before, and disclosed by prior art references not relied on by the Examiner. (*Id.*)

C. The Earliest Possible Priority Date is September 1, 2000

The September 1, 2000 priority date of the '437 patent is the earliest possible priority date (the "EPD") for the Challenged Claims. The subject matter of the Challenged Claims is not supported by its claimed earlier-filed provisional application, Provisional U.S. Application No. 60/152,249 (EX1012, the "'249 provisional application").

Independent claim 1 recites "a purge lumen extending through the catheter," "an elongate lumen associated with the cannula and sized to slidably receive the guide wire and dimensioned such that the guide wire passes slidably and coaxially through the elongate lumen," "the elongate lumen is sized smaller cross-sectionally than the cannula lumen," "both the elongate lumen and the cannula lumen not extending through the rotor hub" and "measuring pressure adjacent the intravascular blood pump." (EX1001['437 patent] 33:55-56, 33:64-67, 33:67-34:1; 34:1-3; 34:25-26.) Yet, nowhere in the '249 provisional application is there support for these limitations. (Collins ¶131; *Dynamic Drinkware, LLC. v. Nat'l Graphics, Inc.*, 800 F.3d 1375, 1378 (Fed. Cir. 2015) ("the specification of the *provisional* must 'contain a written description of the invention and the manner

and process of making and using it, in such full, clear, concise, and exact terms,’
35 U.S.C. § 112 ¶1, to enable an ordinarily skilled artisan to practice the invention
claimed in the provisional application.”) (quoting *New Railhead Mfg., LLC v.*
Vermeer Mfg. Co., 298 F.3d 1290, 1294 (Fed. Cir. 2002) (emphasis in original).)

Accordingly, the EPD for Challenged Claims is September 1, 2000.⁵

(Collins ¶133.)

VII. OVERVIEW OF THE PRIOR ART⁶

A. Overview of Aboul-Hosn

Aboul-Hosn discloses an axial flow intravascular blood pump for heart support, that is delivered intravascularly to a desired location within the heart using the same well-known guide mechanisms as noted in the ’468 patent. (Collins ¶134; EX1004[Aboul-Hosn] 11:9-14; 30:1-2.) Aboul-Hosn further discloses both



⁵ If the Board finds that one or more Challenged Claims is entitled to the September 3, 1999 filing date of the ’249 provisional application, the cited prior art would still qualify as prior art under 35 U.S.C. § 102(a) or 35 U.S.C. § 102(b).

⁶ Aboul-Hosn and Siess were cited in an Information Disclosure Statement dated August 19, 2016 but there is no record that the Examiner relied upon them. (EX1003[’437 PH] 254-274. There is no record of Jegaden, Yock, or Wampler being disclosed during prosecution of the ’437 patent.

percutaneous and surgical approaches for delivering the blood pump. (Collins ¶¶153-57; EX1004[Aboul-Hosn] FIG. 21, 21:19-22:30, 11:8-12.)

Annotated FIGS. 21 and 23, below, show the percutaneous approach using a guide wire. (Collins ¶154; EX1004[Aboul-Hosn] 30:1-2, 20-27.) FIG. 21 shows how the blood pump (green) passes along the guide wire up the femoral artery, so the cannula 411⁷ (blue) goes through the aorta and into the left ventricle. In FIG. 23 the cannula then also continues into the left atrium, where it is positioned to pump blood from the left atrium to the aorta. (Collins ¶¶154-55; EX1004[Aboul-Hosn] 29:17-28, 30:1-2, 30:20-27.) The cannula's inflow tip may be placed in “the left ventricle,... or any of the left heart vessels” to provide left heart support. (*Id.* 26:10-13.)

⁷ FIG. 20 is a zoomed-in view of the stabilization system 410 of FIG. 23; it identifies element 411 as the stabilization cannula that passes through the stabilization balloon 440 (red). (EX1004 [Aboul-Hosn] 28:23-27.)




(Collins ¶154; EX1004[Aboul-Hosn] FIGS. 21, 23, annotated.)

FIGS. 1-13 show the surgical approach with details about the interior of the pump and cannula. Numerous conventional features of intravascular blood pumps are disclosed, including a “commercially available” cannula (EX1004[Aboul-Hosn] 11:14), together with a “reverse flow” feature that reverses the direction of blood flow as it exits the pump. (Collins ¶¶156-57.)

As shown below in FIGS. 1 and 2, and similar to the ‘468 patent, the pump system has a conventional drive motor 80 (purple) connected to a rotor and associated blades 70 (red), within a housing body 52 (green) and a housing cap 62

(green).⁸ (EX1004[Aboul-Hosn] 12:12-13:13; Collins ¶141.) The inner cannula 20 (blue) is coupled to the housing cap 62 (green), and extends beyond the distal opening 32 of the outer conduit 30 (dark grey). (*Id.*)




(Collins ¶141; EX1004[Aboul-Hosn] FIGS. 1, 2, annotated.)

As shown below, to apply the percutaneous approach in the reverse flow configuration, the pump (green) in the system of FIGS. 1-13 (i.e. an intravascular pump “provided for by the present invention”) would be readily connected to the

⁸ The housing body 52 and the housing cap 60 may form “a unitary body.”

(EX1004 [Aboul-Hosn] 12:22-23.)


multilumen catheter 428 (yellow). (Collins ¶150.) In this configuration, the catheter 428 would be used to advance the pump 420 and stabilization cannula 411 over a guide wire to the desired location within the patient's heart through the femoral artery. (*Id.* ¶151; EX1004[Aboul-Hosn] 29:18-25.)



(Collins ¶144; EX1004[Aboul-Hosn] FIGS. 1, 23, annotated.)

The pump 420 could also be configured without the reverse flow feature of the pump system of FIGS. 1-13. (Collins ¶145; *see also* EX1004[Aboul-Hosn] 31:6-9.) In this configuration, the pump 420 would include the components of the pump system of FIGS. 1-13 that generate the axial flow of blood through the pump (i.e. rotor 70 and inlet tube 55, connected to drive unit 80), without the components

that cause the blood flow to reverse course (i.e. housing body 52, housing cap 60, and outer cannula 30). (Collins ¶¶145-47.) Instead, the blood (represented by the red arrows) discharges axially over the drive unit and out the pump 420 (green). (Id. ¶146.)




(Collins ¶145; EX1004[Aboul-Hosn] FIGS. 1, 23, annotated.)

As explained in greater detail in Section X.A.1(l) below, Aboul-Hosn uses a guide wire to deploy the pumps intravascularly using the over-the-wire technique. (Collins ¶¶135-40; EX1004[Aboul-Hosn] 11:26-28, 14:13-16, 14:20-24, 21:22-24, 22:10-16.) FIG. 3 shows the conventional over-the-wire technique. (Collins ¶135; EX1004[Aboul-Hosn] 14:17-15:18, 17:19-22, FIG. 12.)

Aboul-Hosn also suggests inserting a guide wire through cannula opening 27 as seen in FIGS. 1 and 2 to place the pump, consistent with the rapid-exchange technique. (*Id.* ¶¶136-40; EX1004[Aboul-Hosn] 11:24-26: “[a] catheter guide wire may also be extended through the cannula openings 27 to dispose the inner cannula 20 at desired locations.”)

B. Overview of Jegaden

Jegaden discloses placing a conventional axial flow intravascular pump system in a desired location using the conventional rapid-exchange technique. (Collins ¶158; EX1033[Jegaden] 61-62.) As shown in FIG. 2, a guide catheter (i.e. 5F catheter) having a guide wire extending coaxially through its lumen and exiting its distal end is “passed through the distal hole of the cannula and introduced into the femoral artery up to the aorta,” and “[t]hen the cannula is introduced into the femoral artery and is pushed into the aorta, guided by the vasculature catheter” (i.e. the 5F guide catheter). (¶¶159-62; EX1033[Jegaden] 61-62.) The 5F guide catheter and distal hole function as a rapid-exchange guide mechanism for the pump. (Collins ¶160.)




(Collins ¶160; EX1033[Jegaden] FIG. 1, annotated.)

C. Overview of Yock

Yock discloses a conventional rapid-exchange catheter, shown in FIG. 10 below, which includes an elongate tubular member, such as a cannula, and a sleeve (with an interior lumen for a guide wire) secured to the exterior of the tubular member or embedded within the cannula wall itself. (*Id.* ¶167; EX1006[Yock] FIG. 10, 7:64-8:2.) A guide wire is placed in a desired location in the body and inserted through the sleeve, and the catheter is advanced along the guide wire to the desired location. (Collins ¶166; EX1006[Yock] 7:64-8:25.) The orientation of

the sleeve along the side of the cannula allows for the rapid exchange of catheters.

(Collins ¶167; EX1006[Yock] 2:31-37.)



(Collins ¶167; EX1006[Yock] FIG. 10, annotated.)

D. Overview of Siess

Siess also discloses an intravascular blood pump configured to be delivered to a desired location within the patient’s vasculature using a guide wire. (Collins ¶175; EX1005[Siess] 5:55-58.) The pump includes a lumen to deliver a “biocompatible purge fluid[,]...that is pressurized so as to maintain a slow purge rate over the seals of about 1-5ml/hr[,]” to the microaxial pump 10. (*Id.* 8:31-44.) Additionally, it can have “electrical conduits extending therethrough to allow the operation of the drive unit to be monitored and controlled.” (*Id.* 3:16-18, 8:31-38, 11:23-40.)

E. Overview of Wampler

Wampler discloses the Hemopump, introduced in Jegaden, which was the original catheter-based blood pump. (Collins ¶169; EX1007[Wampler] 232-36.) Wampler provides a schematic of the Hemopump in FIG. 14-2, below, showing

purge fluid inlet and outlet conduits connected to a purge fluid pump that delivers a continuous infusion of purge fluid to the Hemopump via lumens within the drive cable sheath. (Collins ¶171; EX1007[Wampler] 233-34.)




Figure 14-2. Schematic of the Hemopump.

(EX1007[Wampler] FIG. 14-2.)

VIII. CLAIM CONSTRUCTION


A claim in IPR is given the “broadest reasonable construction in light of the specification.” (37 C.F.R. § 42.100(b).) Any claim term that lacks a definition in the specification is therefore also given a broad interpretation. (*In re ICON Health & Fitness, Inc.*, 496 F.3d 1374, 1379 (Fed. Cir. 2007).) Consistent with 37 C.F.R.

§ 42.100(b), Petitioner submits the following claim term constructions.⁹ Any claim terms not included in the following discussion are to be given their broadest reasonable construction in light of the specification as commonly understood by those of ordinary skill in the art.

A. “Distal”

The Challenged Claims recite the term “distal.” This term “distal” refers to being directed toward the far end of the cannula relative to the position of the pump. (*Id.* ¶123-25.) Referring to the ’437 patent FIG. 3, below, “the purge fluid flows distally around the cable adapter, through the ball bearing assemblies 50, 52, and onward past the radial seal 64.” (EX1001[’437 patent] 12:34-37.)

FIG. 3



⁹ Petitioner reserves the right to pursue different constructions in a district court, where a different standard applies.


(Collins ¶123; EX1001['437 patent] FIG. 3, annotated.)

The “distal flow” referred to by the '437 patent travels through the blood pump in a direction towards the cannula indicating that the distal direction runs from left-to-right moving away from the pump body towards the opening of the cannula into the patient’s heart. (Collins ¶123.) Moreover, the '437 patent makes numerous references to a “distal end” or “distal tip” with respect to certain components. (*Id.* ¶¶124-25; EX1001['437 patent] 10:27-31, 11:37-39.)

Thus, distal refers to “towards the far end of the cannula relative to the position of the pump.” (Collins ¶126.)

B. “Proximal”

The Challenged Claims also recite the term “proximal.” This term refers to the opposite of “distal,” i.e., it refers to being directed away from the far end of the cannula relative to the position of the pump. (Collins ¶¶127-28.) For example, the '437 patent provides that “[t]he cannula 14 is coupled at its proximal end to the rotor shroud 36,” which is the end opposite the “distal region” of the cannula. (*Id.* ¶128; EX1001['437 patent] 10:27-31, 11:60-61.)



(Collins ¶127; EX1001[’437 patent] FIG. 3, annotated.)

Thus, proximal refers to “away from the far end of the cannula relative to the position of the pump.” (Collins ¶129.)

IX. PERSON HAVING ORDINARY SKILL IN THE ART

A POSITA as of the EPD would have had (i) a Bachelor’s degree in mechanical or biomedical engineering, or a similar field, and two to three years of work experience with intravascular cardiac assist devices, (ii) a Master’s degree in mechanical or biomedical engineering, or a similar field, and two to three years of work experience in medical device or related fields, or (iii) a Ph.D. in mechanical or biomedical engineering, or a similar field. (Collins ¶33.)

X. SPECIFIC GROUNDS FOR PETITION

The below sections demonstrate in detail how the prior art discloses each and every limitation of the Challenged Claims and how those claims are rendered

obvious by the prior art. The declaration by Dr. Collins (EX1002) confirms these analyses and conclusions.

A. Ground I: Claims 7-9, and 11-15 are obvious in over Aboul-Hosn in view of Jegaden, and further in view of Siess and Wampler

1. Claim 1 (Claims 7-9, 11-15 all depend from Claim 1)

- a) *“A method for providing left-heart support using an intravascular blood pump system, wherein the intravascular blood pump system comprises:”*

Aboul-Hosn discloses a method for providing left-heart support using an intravascular blood pump system. (Collins ¶¶226-236; EX1004[Aboul-Hosn] 6:6-8; 6:26-29). The Aboul-Hosn intravascular blood pump system (EX1004[Aboul-Hosn] 6:6-8) can be inserted percutaneously (*Id.* FIG. 23) or surgically (*Id.* FIG. 24). (Collins ¶¶228-29.) Figure 23 demonstrates an intravascular blood pump 420 (green) coupled at its proximal end to cannula 411 (blue) and positioned in the left side of the heart through the femoral artery using a multi-lumen catheter 428 (yellow). (EX1004[Aboul-Hosn] 10:10-11 (“FIG. 23 is a partial sectional view of the heart and a stabilization system used in cooperation with an intravascular pump.”); 29:17-19 (“The stabilization apparatus 410 and a pump 420 may be introduced into the body as shown in FIG. 21 through the femoral artery 430 with a catheter 428 linking the device to the exterior of the body.”).)




FIG. -23

(Collins ¶229; EX1004[Aboul-Hosn] FIG. 23, annotated.)

As discussed below, the various blood pump elements claimed in the '437 patent are disclosed by Aboul-Hosn in view of a small number of other references.

Thus, Aboul-Hosn discloses this limitation. (Collins ¶236.)


- b) *“an intravascular blood pump adapted to be guided to a predetermined location within the circulatory system of a patient by a guide wire and configured to provide left-heart support,”*

Aboul-Hosn discloses that the axial flow blood pump system of FIGS. 1-13, either with or without the reverse flow feature (*See* Section VII.A), can be delivered to the heart percutaneously as shown in FIG. 23. (Collins ¶¶231-35, 237;

EX1004 [Aboul-Hosn] 8:20-9:13, 29:18-30:28, 14:13-16.) Aboul-Hosn discloses extending a guide wire through a lumen to place the blood pump in a desired location within the patient. (Collins ¶238; EX1004[Aboul-Hosn] 11:24-26, 17:19-23, 22:10-16, 24:7-14, 29:23-25.)

The guide wire is first placed in the desired location, and then the distal end of the inner cannula 20 and the pump 50 are guided to the desired location within the patient's vasculature by sliding the inner cannula 20 and pump 50 over the guide wire. (Collins ¶238; EX1004[Aboul-Hosn] 22:12-16) The guide wire can guide the cannula coupled to the pump to any location in the body, including any "blood vessel, heart chamber or other body cavity." (*Id.* 11:8-11, 11:24-28, 22:10-12; Collins ¶240.) This includes the left ventricle or atrium to provide left-heart support in the same conventional manner as disclosed by the '437 patent. (*Id.*; EX1004[Aboul-Hosn] 26:10-13, 29:31-30:2: "[a]fter proper positioning, a pump may be activated to take over the left ventricle function")

As shown in FIGS. 21 and 23 of Aboul-Hosn below, "to take over the left ventricle function," the pump is positioned in the patient's aorta and the cannula extends through the left ventricle and into the left atrium, bypassing the left ventricle. (Collins ¶241.)



(Collins ¶241; EX1004[Aboul-Hosn] FIGS. 21 and 23, annotated.)


Thus, Aboul-Hosn discloses this limitation. (Collins ¶245.)

- c) “the intravascular blood pump comprising a rotor having a rotor hub tapering in the distal direction, at least one blade extending radially outward from the rotor hub, the rotor hub having a distal end extending distally beyond a most distal portion of the at least one blade;”

Aboul-Hosn’s intravascular blood pump has a rotor having a rotor hub.


(Collins ¶¶246-50; EX1004[Aboul-Hosn] 12:30-13:1: “[t]he reverse flow pump 50...includes a rotor 70 axially aligned inside a cylindrical shaped housing body 52.”) FIGS. 7A-7C “illustrate various configurations of a rotor 70 that may be used in a reverse flow pump or any other type of fluid transport apparatus.” (*Id.* 16:30-31.) FIG. 7B (annotated below) shows a rotor 70 having a central hub 74 tapering in the distal direction. (Collins ¶246.)

FIG. 7B illustrates the rotor 70 having three blades 72 each extending radially outward from the central hub 74. (*Id.*; EX1004[Aboul-Hosn] 17:1-2.)



(Collins ¶246; EX1001[’728 patent] FIG. 4, annotated (left); EX1004[Aboul-Hosn] FIG. 7B, annotated (right).)

In addition, FIG. 7B demonstrates that the “rotor hub ha[s] a distal end extending distally beyond a most distal portion of the at least one blade.” Specifically, in FIG. 7B the distal end of the rotor hub (71), extends more distally than any of the blades (72). (Collins ¶247.)



(Collins ¶247; EX1004[Aboul-Hosn] FIG. 7B, annotated.)

Indeed, as Dr. Collins explains, the claimed rotor configuration (i.e. having a tapered hub, blades extending from the surface of the hub) was conventional. (*Id.* ¶248.) Aboul-Hosn also recognizes that the specific configuration of the rotor is not limited, and that a variety of suitable configurations may be used. (*Id.*; EX1004[Aboul-Hosn] 19:28-31.)

Thus, Aboul-Hosn discloses this limitation. (Collins ¶¶249-50.)

- d) “a catheter coupled to a proximal end of the intravascular blood pump,”

Aboul-Hosn discloses an intravascular blood pump 420 (green) coupled to a catheter 428 (yellow) on its proximal end and a cannula 411 (blue) on its distal end. (Collins ¶¶251-55.)




FIG. -23

(Collins ¶253; EX1004[Aboul-Hosn] FIG. 23, annotated.)

As applied to FIG. 23 of Aboul-Hosn, the distal end of the blood pump 420 is the end closest to the distal end 415 of the cannula, and the proximal end of the blood pump is the end away from the distal end 415. (*Id.* ¶253.) Aboul-Hosn shows the catheter 428 directly connected to the proximal end of the pump 420 in FIG. 23. (*Id.* ¶254.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶255.)

e) “a purge lumen extending through the catheter;”

In annotated FIG. 23 below, Aboul-Hosn discloses a catheter 428 (yellow) attached to the intravascular blood pump 420 (green), the catheter 428 “linking the device to the exterior of the body.” (EX1004[Aboul-Hosn] 29:17-19; Collins ¶¶256-58.)




FIG. – 23

(Collins ¶257; EX1004[Aboul-Hosn] FIG. 23, annotated.)

Aboul-Hosn further discloses that “[t]he catheter 428 may be a multilumen catheter with separate lumens to drive the pump 420, to measure pressure in the

vicinity of the catheter along its entire length, *to deliver or remove fluid*, to enable the passage of small diameter guides or leads, or to perform other similar functions.” (Collins ¶258; EX1004[Aboul-Hosn] 29:19-25, emphasis added.) Specifically, Aboul-Hosn discloses using such fluid to lubricate the “drive unit 80 that may be used in accordance with the present fluid control and delivery system.” (Collins ¶259; EX1004[Aboul-Hosn] 20:16-29.) Aboul-Hosn discloses that the fluid is a “biocompatible lubricating fluid,” for example a 40% dextrose solution. (*Id.* 21:1-3.) Dextrose is a commonly used purge fluid to lubricate mechanical parts of the pump. (Collins ¶¶261-62.) Further, a POSITA would understand that the “biocompatible lubricating fluid” of Aboul-Hosn is the “purge fluid” as disclosed by the ’437 patent because it serves the same purposes. (*Id.*)

The ’437 patent discusses that the “purge fluid” serves the dual purpose of “thwart[ing] the ingress of blood past the radial seal **64**, which might otherwise cause clotting and/or pump damage,” and “reduces frictional heating within the pump **12** and/or central lumen **74** of the sheath **32** during pump operation. (EX1001[’437 patent] 12:30-46.) The biocompatible lubricating fluid of Aboul-Hosn serves the same purpose. (Collins ¶¶261-62.) It is self-evident that the biocompatible lubricating fluid acts as a lubricant for the bearings and shaft 81, reducing friction and heat associated with friction, which is why Aboul-Hosn refers to the fluid as a biocompatible lubricating fluid. (*Id.* ¶¶259-62.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶263.)

- f) “a cannula coupled to a distal end of the intravascular blood pump,”

As shown in FIG. 23 reproduced below, Aboul-Hosn discloses an intravascular blood pump 420 (green) coupled to a catheter 428 (yellow) on its proximal end and a cannula 411 (blue) on its distal end. (Collins ¶266; EX1004[Aboul-Hosn] 30:27-28.)






FIG. -23

(Collins ¶266; EX1004[Aboul-Hosn] FIG. 23, annotated.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶¶267-69.)

- g) *“one or more first ports and one or more second ports establishing fluid communication between a cannula lumen and an exterior region of the cannula, wherein at least one first port is located in proximity to the rotor and at least one second port is spaced apart from and located distal to the at least one first port; and”*

As discussed above Section VII.A, the axial blood pump components of FIGS. 1-13 with or without the reverse flow feature can be used for the blood pump 420. (Collins ¶270.) As shown in FIGS. 3 and 23 below, in operation, for either the axial flow pump with or without the reverse flow feature, blood enters the cannula through openings at its distal end 415, and is pushed by the rotor of the pump 420 through outflow windows of the pump housing and exits the proximal end of the pump 420. (*Id.* ¶¶271-276; EX1004[Aboul-Hosn] 11:21-24: “a plurality of openings 27 formed near its tip 25 to allow blood to flow into the inner cannula 20”; 13:6-13; 13:15-18: “[d]uring operation of the fluid control apparatus in this configuration, the rotor 70 is rotated by the driving unit 80 through an opening or hole 54 in order to direct fluids such as blood”.)



(Collins ¶277; EX1004[Aboul-Hosn] FIGS. 3, 23, annotated.)

When the pump 420 is actuated, blood flows through the distal opening 22, openings 27, and outflow windows in the pump housing, thereby establishing fluid communication between a lumen of the inner cannula 20 and an exterior region of the inner cannula 20 during operation of the blood pump 420. (Collins ¶¶272-75.) Moreover, as shown in FIGS. 3 and 23, Aboul-Hosn discloses that for both the axial flow pump with or without the reverse flow feature, the distal opening 22 and openings 27 are located at the distal region of the cannula, whereas the outflow windows are located at the opposite end of the blood pump 420 adjacent the rotor 70 within the housing body 62. (*Id.* ¶¶276-77.)

Thus, when the pump is activated, the distal opening 22 along with openings 27 are “one or more second ports,” and the outflow windows would be “one or more first ports,” where the one or more first ports and the one or more second ports establishing fluid communication between a lumen of the cannula and an exterior region of the cannula, and at least one first port is in proximity to the rotor and at least one second port is spaced apart from and located distal to the at least one first port. (*Id.* ¶278.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶279.)

- h) “*an elongate lumen associated with the cannula and sized to slidably receive the guide wire and dimensioned such that the guide wire passes slidably and coaxially through the elongate lumen,*”

The '437 patent does not specify what it means to be an *elongate lumen*, much less an elongate lumen *associated with* the cannula. (Collins ¶280.)

Notwithstanding, Aboul-Hosn in view of Jegaden, discloses the “elongate lumen associated with the cannula” as recited by this limitation in the same manner as the '437 patent. (*Id.*)

Aboul-Hosn discloses how a blood pump system may be placed in a desired location within a patient by using a guide wire that passes through an elongate lumen. (Collins ¶¶281-286; EX1004[Aboul-Hosn] 11:24-28; 17:19-21; 24:7-14.) Aboul-Hosn teaches delivering the intravascular blood pump using the over-the-wire technique, and further suggests delivering the intravascular blood pump using the rapid-exchange technique. (Collins ¶¶282-86; EX1004[Aboul-Hosn] 11:24-26; 17:8-22; 20:23-26; 24:7-14;) In the context of FIG. 1 Aboul-Hosn discloses that “[a] catheter guide wire may also be extended through the cannula openings 27 to dispose the inner cannula 20 at desired locations throughout the body including the heart region.” (*Id.* 11:24-26.) Moreover, FIG. 1 does not illustrate the rotor hub 70 having a guide wire extending through it, as compared to FIG. 3 which illustrates an over-the-wire configuration. (*C.f. id.* FIG. 1 *with* FIG. 3.) As such, a POSITA would understand that the catheter guide wire “extended through the

cannula opening 27” but not through the rotor hub 70 is consistent with a rapid-exchange configuration. (Collins ¶285.)

This is the same rapid-exchange mechanism disclosed by Jegaden and would also include an elongate lumen according to this claim element. (Collins ¶¶287-91.) Jegaden discloses a 5F catheter having a guide wire that extends coaxially through its lumen (i.e. an elongate lumen) and exits its distal end, where that catheter is “passed through the distal hole of the cannula and introduced into the femoral artery up to the aorta,” and “[t]hen the cannula is introduced into the femoral artery and is pushed into the aorta, guided by the vasculature catheter” (i.e. the 5F guide catheter). (Collins ¶¶288-291; EX1033[Jegaden] 61-62.) A POSITA would understand that the guide wire of Jegaden would be placed within the elongate lumen of the 5F catheter by sliding. (Collins ¶291.)

As Dr. Collins shows in FIGS. 1 and 2 of Jegaden and FIG. 1 of Aboul-Hosn below, the distal hole of Jegaden’s cannula is the same as the opening 27 at the distal region of Aboul-Hosn’s cannula, and as such, Aboul-Hosn’s “catheter guide wire” can be used in a similar manner as shown in Jegaden (as illustrated by the superposition of the distal end of Jegaden’s cannula onto Aboul-Hosn’s cannula) to place the intravascular blood pump. (*Id.* ¶292; EX1004[Aboul-Hosn] 11:24-26.)




Fig. 1.




FIG. -1

(Collins ¶292.)

Jegaden's 5F catheter contains an elongate lumen through which the guide wire extends and the elongate lumen is associated with the cannula, satisfying this claim element. (Collins ¶¶290-92.)


A POSITA would have been motivated to apply Jegaden's teachings of extending a guide wire and catheter through the opening 27 at the distal end of Aboul-Hosn's cannula to guide Aboul-Hosn's pump using the rapid-exchange technique at least because: (1) both Jegaden and Aboul-Hosn are directed to the placement of intravascular blood pumps; (2) both expressly disclose extending a guide wire through a distal opening (e.g. Aboul-Hosn's opening 27) consistent

with rapid exchange; and (3) Jegaden further discloses that its guide catheter insertion technique is “easy, safe, and fast to use in all cases, especially when fluoroscopic guidance can be avoided,” which are well-known advantages of a rapid-exchange mechanism. (*Id.* ¶¶204-12; EX1004[Aboul-Hosn] 11:24-26; EX1033[Jegaden] 63.)

Additionally, Aboul-Hosn discloses a number of side lumens in the cannula that “may be formed adjoining to or concentric with the cannula 20,” and would, therefore, also be elongate lumens according to the claim. (Collins ¶¶293-96; EX1004[Aboul-Hosn] 28:10-12.) For example, FIG. 19 of Aboul-Hosn shows cannula 20 with passageway 198 that provides a therapeutic agent to the patient. (Collins at ¶295; EX1004[Aboul-Hosn] 27:23-28:12.)

A POSITA would readily appreciate that existing therapeutic agent lumens within the wall of the cannula can be easily used for a guide wire in a rapid-exchange configuration in light of Aboul-Hosn’s general teaching that the functions of the various lumens of the intravascular blood pump can be used for a variety of purposes, including delivering fluid and guide wires. (Collins ¶221; EX1004[Aboul-Hosn] 27:31-28:18; 29:19-25.) Indeed, using lumens interchangeably for fluid or guide wires was well-known at the time. (Collins ¶¶139, 294; U.S. Patent No. 6,544,216 to Sammler (EX1018, “Sammler”) at 5:9-17.)

A POSITA would thus readily understand that the existing lumens of Aboul-Hosn's cannula could be used for delivering the guidewire, just as well as the lumen of Jegaden. (Collins ¶294.) The guide wire would extend proximally along the cannula and enter a side lumen in the wall of the cannula through an opening (such as a port 187 formed in the sidewall of the cannula), slide coaxially through the lumen, and exit the side lumen through its distal end. (*Id.* ¶220.)



(Collins ¶220; EX1004[Aboul-Hosn] FIG. 20, annotated.)




FIG. - 19

(Collins ¶295; EX1004[Aboul-Hosn] FIG. 19, annotated.)

As in the case of Jegaden's 5F catheter, the guide wire would guide the distal end of the cannula into a desired position within the patient's body. (Collins ¶295; EX1004[Aboul-Hosn] 11:24-26; EX1033[Jegaden] 62.) Similarly, a

POSITA would understand that the same configuration can be applied to the percutaneous approach shown in FIG. 23, below, where a guide wire would similarly extend proximally along the side of the cannula, enter a side lumen in the wall of the cannula (e.g. the side lumen shown in FIG. 20, above) through an opening, slide through the length of the lumen, and exit the side lumen through its distal end in order to facilitate the placement of the intravascular blood using the rapid-exchange technique. (Collins ¶¶222, 296.)




FIG. - 23

(Collins ¶296; EX1004[Aboul-Hosn] FIG. 23, annotated.)

As discussed above, while over-the-wire and rapid-exchange are interchangeable guidance techniques, there were known advantages of using rapid-exchange, compared to over-the-wire. (Collins ¶¶99, 297.) Rapid-exchange allows the procedure to be carried out by a single person instead of two as rapid-exchange does not require pre-loading the guide wire through the intravascular blood pump (which is typically equal in length to the length of the guide wire entering the patient's body). (*Id.*) Thus, rapid-exchange reduces the required length of the guide wire (*Id.*), and also reduces the required sterilization area for performing the procedure. (*Id.*; EX1006[Yock] 1:15-25.) Accordingly, the procedure is simplified. (Collins ¶¶99, 297; EX1023[Faxon] 59.) Moreover, compared to over-the-wire, rapid exchange does not require a central lumen to pass through the pump and the rotor and as such, provides additional design flexibility (e.g. using a smaller diameter rotor hub, eliminating the need to provide a seal in the rotor, etc.) (Collins ¶100.)

Thus, a POSITA would have been motivated to place Aboul-Hosn's intravascular blood pump using the rapid-exchange technique, either by using a catheter guide wire (e.g. a 5F guide catheter) through opening 27 at the distal region of the cannula or by passing a guide wire through an existing side lumen within the cannula and exiting the distal end of the cannula, as disclosed by Aboul-Hosn and Jegaden. (Collins ¶¶204-13.)

In either rapid-exchange configuration, the elongate lumen (i.e. lumen of the 5F guide catheter or a side lumen of the cannula) is associated with the cannula (i.e. the catheter lumen is associated with the cannula where the catheter guide wire passes through the opening 27 in the cannula, or the side lumens are formed within the sidewall of the cannula). (Collins ¶¶290, 293; EX1004[Aboul-Hosn] 11:24-26, 28:7-12.) Moreover, the 5F guide catheter lumen and side lumen of the cannula are dimensioned such that the guide wire passes slideably and coaxially through. (Collins ¶¶291, 293, 298.) Thus, Aboul-Hosn in view of Jegaden, discloses this limitation. (*Id.* ¶298.)

- i) *“the elongate lumen is sized smaller cross sectionally than the cannula lumen,”*

Aboul-Hosn in view of Jegaden discloses this limitation. (Collins ¶¶299-303.) When using the preferred rapid-exchange technique, the elongate lumen may either be (1) the catheter lumen of the catheter guide wire passing through the opening 27 in the cannula, or (2) a side lumen within the wall of the cannula. (*Id.* ¶300.) Both lumens have smaller cross-sections than the cannula lumen. (*Id.*) With respect to the 5F guide catheter lumen, as Dr. Collins shows below in FIG. 1 of Jegaden and Aboul-Hosn, the catheter lumen that passes through the distal opening 27 of Aboul-Hosn’s cannula has a cross-section that is smaller than a cross-section of the cannula. (*Id.* ¶¶300-01.)

Indeed, a POSITA would expect the cross section of the 5F guide catheter lumen or side lumen to be sized smaller than the lumen of the cannula given the limited space within the patient's vasculature, and the majority of the space would be used for the components that provide the blood pumping function (i.e. the cannula, the rotor blades, etc.) (Collins ¶302.) This is confirmed by FIG. 1 of Jegaden and FIGS. 1 and 20 of Aboul-Hosn, above.

Accordingly, Aboul-Hosn in view of Jegaden, discloses this limitation. (Collins ¶303.)

- j) *“both the elongate lumen and the cannula lumen not extending through the rotor hub;”*

This limitation is a characteristic feature of a rapid-exchange guide mechanism applied intravascular blood pumps, and is disclosed by Aboul-Hosn in view of Jegaden. (Collins ¶¶304-10.) As Dr. Collins shows below in FIG. 2 of Jegaden and FIG. 1 of Aboul-Hosn, where the catheter guide wire extending through cannula 27 is used, the elongate lumen (i.e. 5F guide catheter lumen) does not extend through the rotor hub because the elongate lumen runs alongside the intravascular blood pump. (*Id.* ¶¶305-307.) The cannula lumen also does not extend through the rotor hub because the cannula is coupled to the rotor housing, and as such, the cannula lumen does not extend through the rotor hub within the rotor housing. (*Id.* ¶ 307.)

This is also the case where the side lumens of the cannula are used to pass the guide wire as shown in FIG. 23 of Aboul-Hosn, reproduced below. (*Id.* ¶307.)




FIG. -23

(Collins ¶307; EX1004[Aboul-Hosn] FIG. 23, annotated.)

Thus, Aboul-Hosn in view of Jegaden, discloses this limitation. (*Id.* ¶310.)

- k) “wherein the method for providing left-heart support comprises the steps of: passing the guide wire into the patient such that a distal end of the guide wire is positioned in the left ventricle of the patient's heart;”

This limitation is simply the recitation of the conventional step of delivering a guide wire through the circulatory system to the left ventricle of the heart. (Collins ¶311.) Aboul-Hosn describes that the guide wire is inserted to the desired location before the cannula is positioned (using the guide wire). (Collins ¶¶311-313; EX1004[Aboul-Hosn] 22:12-14 (“The guide wire 28 may be inserted and positioned to a desired location before being passed through an opening or orifice formed on the distal end of the inner cannula 20.”)) Aboul-Hosn further describes that the guide wire may be advanced to a specific location within the patient, including any heart chamber or blood vessel or artery. (Collins ¶312; EX1004[Aboul-Hosn] 11:8-11, 11:24-28, and 22:10-14.)

One of the locations in which Aboul-Hosn positions the distal tip of the cannula is the left ventricle. (Collins ¶313; EX1004[Aboul-Hosn] 26:10-13, 29:31-30:2: “[m]eanwhile, the stabilization cannula 411 may be positioned within a ventricle or atrium. After proper positioning, a pump may be activated and take over the left ventricle function.”) When the cannula is delivered to the left ventricle, the guide wire would conventionally be delivered to that ventricle such that the distal end of the guide wire is in the left ventricle. (Collins ¶313.) The cannula would then follow. (*Id.*)

Accordingly, Aboul-Hosn discloses this limitation. (*Id.* ¶314.)

- 1) *“placing the guide wire through both the cannula and the elongate lumen such that the guide wire extends*

proximally away from the intravascular blood pump, the guide wire not passing through the rotor hub or the catheter, and the guide wire extends out of the intravascular blood pump system in a distal direction through the elongate lumen;”

This limitation simply recitates the conventional step necessary to use a conventional side rigger guide mechanism. (Collins ¶315.) As discussed in Section X.A.1(h), Aboul-Hosn in view of Jegaden, discloses an elongate lumen where the guide wire passes through both the elongate lumen and cannula. Moreover, as shown in FIG. 2 of Jegaden and FIG. 1 of Aboul-Hosn below, the guide wire along with the catheter extends proximally away from the intravascular blood pump. (*Id.* ¶316.)




Fig. 2.

(Collins ¶316; EX1033[Jegaden] FIG. 2, annotated.)




FIG. -1

(Collins ¶317.)

Continuing, as discussed in Section X.A.1(j), Aboul-Hosn in view of Jegaden, discloses that the elongate lumen does not pass through the rotor hub. The guide wire is designed to pass through the elongate lumen, which is designed so as to not pass through the rotor hub, thus the guide wire does not pass through the rotor hub. (*Id.* ¶317.) Further, as shown in FIG. 2 of Jegaden above, the guide wire does not pass through the rotor hub or the catheter coupled to the proximal end of the pump. (*Id.* ¶318.)

This is also the case where the side lumens of the cannula are used to pass the guide wire as shown in FIG. 23 of Aboul-Hosn, reproduced below. (*Id.* ¶319.)




FIG. -23

(Collins ¶319; EX1004[Aboul-Hosn] FIG. 23, annotated.)

Lastly, in either rapid-exchange configuration, the guide wire extends out of the intravascular blood pump system in a distal direction through the distal end of the catheter lumen (as shown in FIG. 1 of Aboul-Hosn and FIGS. 1 and 2 of Jegaden, above) or the distal end of the side lumen (as shown in FIG. 23 of Aboul-Hosn, above.) (*Id.* ¶319.)

Thus, Aboul-Hosn in view of Jegaden, discloses this limitation. (*Id.* ¶320.)

- m) *“advancing the cannula into the patient using the guide wire and positioning the cannula across an aortic valve of the patient such that a distal end of the cannula and the at least one second port are positioned in the left ventricle and a proximal end of the cannula and the at least one first port are positioned in the aorta;”*

Again, this limitation simply recites the conventional step of delivering the blood pump system through the circulatory system to the left ventricle of the heart using the positioned guide wire. (Collins ¶321.) Aboul-Hosn discloses that once the guide wire is positioned, the cannula can be guided into position using the guide wire. (*Id.*; EX1004[Aboul-Hosn] 22:12-16 (“The guide wire 28 may be inserted and positioned to a desired location before being passed through an opening or orifice formed on the distal end of the inner cannula 20. As a result, the distal end of the inner cannula 20 may be guided to a location before removing the guide wire 28.”))

As shown in FIGS. 21 and 23, reproduced below, when providing left heart support the pump 420 is positioned in the patient’s aorta and the cannula extends through the left ventricle and into the left atrium. (Collins ¶322.)

disclosed by the '437 patent. (Collins ¶¶240, 324; EX1004[Aboul-Hosn] 26:10-13, 29:31-30:2; EX1001['437 patent] 20:45-50.)

Thus, Aboul-Hosn discloses this limitation. (Collins ¶325.)

- n) *“passing purge fluid through the purge lumen to the intravascular blood pump;”*

This feature recites the conventional use of a purge lumen in blood pumps – passing purge fluid through a tube. (Collins ¶326.) As discussed above in Section X.A.1(e), Aboul-Hosn discloses a purge lumen extending through the catheter, whose purpose is to deliver purge fluid to the blood pump. (Collins ¶¶256-63, 327-328; EX1004[Aboul-Hosn] 20:16-29.) Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶329.)


- o) *“measuring pressure adjacent the intravascular blood pump; and”*

Measuring blood pressure to aid in controlling the operation of the pump was well-known and Aboul-Hosn discloses several examples of measuring it adjacent the blood pump. (Collins ¶¶331-35.) The Aboul-Hosn catheter 428 has multiple lumens to perform various functions related to the operation of the intravascular blood pump 420, including “to measure pressure in the vicinity of the catheter along its entire length,” which would include the area adjacent the blood pump 420. (*Id.* ¶332; EX1004[Aboul-Hosn] 29:19-24.) Moreover, an “orifice 187 may be positioned anywhere along the cannula 20 surfaces,” also adjacent the

pump 420, and may be “used as ... a port for measuring pressure in areas proximal to the surface.” (Collins ¶332; EX1004[Aboul-Hosn] 28:14-17.) The Aboul-Hosn pump “may also be equipped with sensing devices (not shown) for measuring various body conditions such as the blood pressure” such as “pressure sensors along the inner cannula 20.” (Collins ¶337; EX1004[Aboul-Hosn] 23:4-10.) Since the proximal end of the cannula couples to the pump, positioning sensors along the inner cannula would necessarily include the position at the proximal end of the cannula, where they connect to the pump 420, to obtain the most accurate reading of pump 420’s output. (Collins ¶¶337, 339.)

Siess confirms this well-understood preference for measuring blood pressure near the pump. (*Id.* ¶¶338-39.) Siess discloses positioning “a first pressure sensor” at “the surface of the drive unit 11 near the pumping segment discharge 140” and “a second sensor 104... near the inlet of the pump housing.” (*Id.* ¶339; EX1005[Siess] 11:25-28.) Siess further teaches that “[w]ith the information provided by such sensors, it is possible to discern the position of the pump relative to the external sealing member such as the heart valve” and “[b]y comparing the pressure differential to the current drawn by the motor, it is possible to identify blockage conditions as well as cavitation.” (*Id.* 11:41-56.) While the sensors in Siess communicate with the control module through sensor conductors 106 and

162 instead of a fluid column, Siess demonstrates that it was preferred to measure the blood pressure near the pump to control the operations of the pump.



(Collins ¶339; EX1005[Siess] FIG. 15, annotated.)



It would have been obvious for a POSITA to measure the blood pressure adjacent Aboul-Hosn blood pump 420 with either the multilumen catheter 428 or the sensors in the cannula in the manner shown in FIG. 15 of Siess. (Collins ¶339.) Moreover, a POSITA would have been motivated to do so “to discern the position of the pump” and to “identify blockage conditions as well as cavitation” by

comparing the pressure differential to the current drawn by the motor as taught by Siess. (*Id.*)

Thus, Aboul-Hosn in view of Siess, discloses this limitation. (*Id.* ¶340.)



- p) “spinning the rotor so as to pump blood from the patient's heart into the at least one second port through the cannula lumen and out the at least one first port to provide left-heart support.”

This limitation recites nothing more than the conventional actuation of a rotor once the blood pump has been positioned as previously set forth in Section X.A.1(l) and (m). (Collins ¶342.) Aboul-Hosn not only discloses the positioning of the cannula for left-heart support (Section X.A.1(m)), but also spinning a rotor to pump blood. (*Id.* ¶343-44.)



(Collins ¶¶345; EX1004[Aboul-Hosn] FIGS. 21 and 23, annotated.)

In the configuration shown above, the distal end of the cannula and the at least one second port at the distal end of the cannula are positioned in the left side of the patient's heart (i.e. the left ventricle), and the at least one first port (i.e. the outflow windows) and the pump are positioned in the aorta. (Collins ¶346; EX1004[Aboul-Hosn] 29:31-30:2.) In operation, as shown below in FIGS. 3 and 23 for either an axial flow pump with or without the reverse flow feature, Aboul-Hosn's blood pump draws blood through the distal opening (i.e. at least one second port) of the cannula by the rotation of the rotor and associated blades of the pump driven by the pump motor which generates an axial flow of blood that exits the pump out of the outflow windows of the pump.. (Collins ¶346; EX1004[Aboul-Hosn] 13:14-18, 18:15-19.)



(Collins ¶346; EX1004[Aboul-Hosn] FIGS. 3, 23, annotated.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶347.)

2. Claim 7

Claim 7 depends from claim 1 and recites “*further comprising the step of inserting a guide catheter into the patient, wherein the guide wire is placed in the patient through the guide catheter.*”

As previously discussed in Sections X.A.1(m) and (k), Aboul-Hosn discloses advancing the pump and cannula to the desired location along the positioned catheter guide wire through a distal opening 27 at the distal end of Aboul-Hosn’s cannula consistent with the rapid-exchange technique, for example as disclosed by Jegaden. (Collins ¶285; EX1004[Aboul-Hosn] 11:24-26.) Jegaden discloses that the guide wire may be advanced via a 5F guide catheter to a desired location within the patient’s heart so that the pump can be positioned in the desired location as shown below in FIG. 2. (Collins ¶350; EX1033[Jegaden] FIG. 2.)




Fig. 2.

(Collins ¶349; EX1033[Jegaden] FIG. 2., annotated.)

Specifically, Jegaden discloses “a guidewire and a 5F catheter are passed through the distal hole of the cannula and introduced into the femoral artery up to the aorta (FIG. 1). Then the cannula is introduced into the femoral artery and is pushed into the aorta, guided by the vasculature catheter” (i.e. guide catheter). (Collins ¶349; EX1033[Jegaden] 62.)


Thus, Aboul-Hosn in view of Jegaden, discloses this limitation. (Collins ¶351.)

3. Claim 8

Claim 8 depends from claim 1 and recites “*further comprising the step of calculating blood pressure adjacent the intravascular blood pump.*”

As previously discussed in Section X.A.1(o), Aboul-Hosn in view of Siess discloses “measuring pressure adjacent the intravascular pump.” (Collins ¶353.) As Dr. Collins explains, the methods of measuring and calculating blood pressure near the pump were well-known and a POSITA would find it obvious to calculate the blood pressure near the pump as measured using the techniques disclosed by Aboul-Hosn as doing so would have simply been the application of a known technique as disclosed by Aboul-Hosn to yield a predictable result. (Collins ¶¶353-55; EX1004[Aboul-Hosn] 23:4-10, 28:14-17, 29:19-24).

For example, Aboul-Hosn teaches one technique for measuring pressure using the intravascular blood pump by forming an orifice in the surface of the cannula 20 to “measure pressure in areas proximal to the orifice” where the orifice 187 “may be positioned anywhere along cannula 20 surfaces.” (EX1004[Aboul-Hosn] 28:12-18.) Aboul-Hosn discloses that the orifice 187 that connects to a fluid source located outside the patient to allow for delivery of fluids such as medication or drugs during surgery. (Collins ¶¶76, 354; EX1004[Aboul-Hosn] FIG. 19, 27:8, 27:14-20, 28:1-2, 28:9-10.) Thus, orifice 187, when used to measure pressure, would be a point of entry of fluid that similarly communicate through a fluid column with a pressure detector located outside the body as illustrated below. (Collins ¶¶76, 354.)



(Collins ¶354; EX1004[Aboul-Hosn] FIG. 19, annotated.)

A POSITA would use the known principles of fluid mechanics to calculate the pressure adjacent the orifice 187 measured by the sensor as shown above. (Collins ¶355; EX1032[White] 89.) Indeed, as Dr. Collins also explains, the mechanisms by which pressure can be determined are (1) measuring directly using sensors or the like, or (2) calculating pressure based on certain pump characteristics, electrical power applied to the pump, or using the principles of fluid dynamics depending on the specific configuration used. (Collins ¶355.) These techniques for pressure measurement were well-known, and calculating the pressure adjacent the orifice 187 using known principles of fluid mechanics would have been obvious to a POSITA. (*Id.*)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶356.)

4. Claim 9

Claim 9 depends from claim 1 and recites “*further comprising the step of removing the guide wire from the patient after the cannula is advanced into the patient.*”

This limitation discloses nothing more than the conventional step of removing the guide wire once the pump has been positioned using the guide wire. (Collins ¶357.) As previously discussed in Sections X.A.1(h) and X.A.1(m), Aboul-Hosn in view of Jegaden discloses that the guide wire slidably and coaxially passes through the elongate lumen to guide the pump and that the cannula advances along the guide wire. Once the cannula and pump are positioned using the guide wire, Aboul-Hosn discloses that the guide wire is removed. (Collins ¶358; EX1004[Aboul-Hosn] 22:12-16: “[a]s a result, the distal end of the inner cannula 20 may be guided to a location before removing the guide wire 28.”)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶359.)

5. Claim 11

Claim 11 depends from claim 1 and recites two additional limitations:

- a) “*wherein the cannula is reinforced with a spiral wire and*”

Aboul-Hosn discloses that the cannula 411 “is formed of a reinforced wire 418” to “provide some degree of kink resistance.” (EX1004[Aboul-Hosn] 28:23-27, 29:4-7; Collins ¶365.) A cross-section of the cannula 411 is shown in FIG. 20,

below. (*Id.* ¶367.)




FIG. -20

(Collins ¶367; EX1004[Aboul-Hosn] FIG. 20, annotated.)

A POSITA would have understood that the reinforced wire 418 is a spiral wire. (Collins ¶¶368-70.) First, Aboul-Hosn refers to the reinforced wire 418 in the singular, and in order for a singular reinforced wire 418 to produce the cross section shown in FIG. 20, the reinforced wire 418 is wrapped in a spiral within the stabilization cannula 411. (*Id.* ¶368.) Second, as shown in FIG. 20, the upper row of circles representing the reinforced wire 418 is offset from the lower row, also indicating that the reinforced wire is wrapped spirally as it extends through the stabilization cannula 411. (*Id.* ¶369.) Third, 25 wire cross-sections of the

reinforced wire 418 are shown in the upper row, whereas 23 wire cross-sections of the reinforced wire 418 are shown in the lower row, which is consistent with a coiled wire (as opposed to a series of rings which would have an equivalent number of wire cross-sections in the upper and lower rows). (*Id.*)

Indeed, it was well-known in the art that a cannula reinforced with a spiral wire when embedded within the wall of the cannula “imparts significant resistance to radial deformation.” (*Id.* ¶370; EX1013[Siess ’359] 6:37-43.) Thus, to “provide some degree of kink resistance” with Aboul-Hosn’s reinforced wire 418, the reinforced wire 418 would have been configured as a spiral wire within Aboul-Hosn’s stabilization cannula 411 in view of well-known teachings of the prior art. (Collins ¶370; EX1004[Aboul-Hosn] 28:23-25, 29:4-7.)


Thus, Aboul-Hosn discloses this limitation. (Collins ¶371.)

- b) *“wherein the purge lumen is a side lumen extending longitudinally through the catheter but offset radially from a central axis of the catheter.”*

As previously discussed in Section X.A.1(e), above, Aboul-Hosn discloses the multilumen catheter 428 coupled to the distal end of the pump has purge fluid lumens, in addition to other lumens for driving the pump, measuring pressure, delivering a guide wire, etc., that are in fluid communication with the pump and arranged to deliver purge fluid to the pump. (Collins ¶373; EX1004[Aboul-Hosn] 29:19-25.) A POSITA would understand that the lumens within the multilumen

catheter 428 would have been radially offset from the central axis of the catheter to conserve space, and that doing so would have been a matter of design choice.

(Collins ¶373.) For example, FIG. 14-2 of Wampler, below, shows a cross section of a catheter coupled to the distal end of the Hemopump having “four outer lumens in the sheath” (i.e. catheter) configured to deliver a continuous infusion of purge fluid (“[a]pproximately 300 cc/day of D40W”) to the pump. (EX1007[Wampler] 234; Collins ¶374.)



(Collins ¶374; EX1007[Wampler] FIG. 14-2, annotated.)

These “four outer lumens” (i.e. side lumens) are offset radially from a central axis of the catheter. (Collins ¶374.) Thus, Aboul-Hosn in view of Wampler discloses this limitation. (*Id.* ¶375.)

6. Claim 12

Claim 12 depends from claim 1 and recites “*wherein the intravascular blood pump further comprising a pressure sensing element configured to sense pressure proximate the intravascular blood pump, the pressure sensing element comprising at least one of a piezoelectric pressure sensing element and a strain gauge.*”

Aboul-Hosn discloses that pressure can be measured in the intravascular blood pump by using pressure sensors to detect the blood pressure. (Collins ¶376; EX1004[Aboul-Hosn] 23:4-8 “[t]he pump 50 may be also be equipped with sensing devices (not shown) for measuring various body conditions such as blood pressure...that would suggest the need for altering the flow rate of the fluid transport apparatus 10.”) Aboul-Hosn’s blood pressure sensors, which can be located anywhere along the inner cannula 20, i.e. which could be located within the pump 50 itself, detects the pressure of the blood proximate the blood pump and cannula. (Collins ¶380; EX1004[Aboul-Hosn] 23:8-10.) Siess also discloses the use of pressure sensors positioned at the desired pressure measurement location. (Collins ¶¶382-83; EX1005[Siess] 4:28-38; 11:23-40.)

A POSITA would understand that the pressure sensors of Aboul-Hosn and Siess could be piezo-electric pressure sensing elements. (Collins ¶¶385-86.) Such devices were well-known in the art for measuring pressure in intravascular blood pumps. (*Id.* ¶385.) Indeed, the ’437 patent concedes that pressure transducers

comprising “a piezo-electric crystal housed in an integrated circuit (IC) chip” are “of the type known in the art,” and that “[d]ifferential pressure transducers are also well known in the art and comprise for example a piezo-electric crystal electro-mechanically configured to be responsive to a pressure difference between two opposing sides thereof.” (EX1001[’437] 30:25-30, 31:60-64; Collins ¶386.) As such, it would have been obvious to a POSITA to use a piezoelectric pressure sensing element as the pressure sensors along the inner cannula 20 of Aboul-Hosn, and doing so would have simply been a straightforward application of a well-known type of pressure sensor to Aboul-Hosn’s intravascular blood pump to yield predictable results. (*Id.*)

Thus, Aboul-Hosn in view of Siess discloses this limitation. (*Id.* ¶387.)


7. Claim 13

Claim 13 depends from claim 12, which depends from claim 1, and recites “*wherein the pressure sensing element further comprising a fluid column extending through the catheter.*”

The ’437 patent is silent what constitutes the “fluid column,” and how the “fluid column extend[s] through the catheter.” (Collins ¶388.) Under the BRI standard, we assume this limitation requires the elongate catheter to have a fluid column for transmitting blood pressure near the blood pump (*Id.*), which Aboul-Hosn discloses. The Aboul-Hosn catheter 428 has multiple lumens to perform

various functions related to the operation of the intravascular blood pump 420, including “to measure pressure in the vicinity of the catheter along its entire length,” i.e. a blood pressure lumen. (*Id.* ¶389; EX1004[Aboul-Hosn] 29:19-24.) As Dr. Collins explains, a POSITA would understand that the lumen inside the multilumen catheter 428 used “to measure pressure in the vicinity of the catheter” is filled with fluid so that the pressure can be measured hydrostatically. (Collins ¶¶389-92.)

Indeed, as previously discussed above in Section X.A.3, Aboul-Hosn teaches one technique for measuring pressure using the intravascular blood pump by forming an orifice in the surface of the cannula 20 to “measure pressure in areas proximal to the orifice” where the orifice 187 “may be positioned anywhere along cannula 20 surfaces.” (EX1004[Aboul-Hosn] 28:12-18.) Aboul-Hosn discloses that the orifice 187 that connects to a fluid source located outside the patient to allow for delivery of fluids such as medication or drugs during surgery. (Collins ¶392; EX1004[Aboul-Hosn] FIG. 19, 27:8, 27:14-20, 28:1-2, 28:9-10.) Thus, orifice 187, when used to measure pressure, would be a point of entry of fluid that similarly communicate through a fluid column with a pressure detector located outside the body as illustrated below. (Collins ¶391.)



(Collins ¶391; EX1004[Aboul-Hosn] FIG. 19, annotated.)

The same teaching is equally applicable to the multilumen catheter 428.

(Collins ¶392.) That is, a POSITA would understand from Aboul-Hosn's disclosure that a similar orifice can be formed on the surface of the multilumen catheter 428 that intersects the blood pressure lumen, allowing a pressure detector located outside the body to measure the pressure near the orifice using the blood pressure lumen. (*Id.* ¶¶393-94.)

Moreover, as indicated by Dr. Collins, a POSITA would understand that the mechanisms for measuring pressure in Aboul-Hosn, such as the fluid columns disclosed in Aboul-Hosn, may be combined with the pressure sensors of Aboul-Hosn or Siess.¹⁰ (*Id.* ¶395.) For example, a POSITA would appreciate that one or

¹⁰ As discussed in Section X.A.6, these pressure sensors may be piezo-electric pressure sensing elements. (Collins ¶¶385-86.)

more of the piezo-electric sensing elements may be used to measure the pressure in the fluid columns of Aboul-Hosn in a similar manner as they would measure pressure within Aboul-Hosn's cannula 20. (*Id.*)

It would have also been obvious to a POSITA to use both piezo-electric pressure sensors along the inner cannula 20 and the fluid columns within the multilumen catheter proximate Aboul-Hosn's intravascular blood pump to measure the pressure differential between the inlet and outlets of the pump. (*Id.*) As disclosed by Siess, "[i]nformation relating to the inlet and outlet pressure" of the intravascular blood pump "provides a wealth of information relevant to the function of the pump device," including the ability "to discern the position of the pump relative to the external sealing member such as the heart valve" to ensure that the pump is properly placed, and the ability to "identify blockage conditions as well as cavitation." (EX1005[Siess] 11:42-56, 12:8-20.)

Thus, Aboul-Hosn in view of Siess discloses this limitation. (*Id.* ¶396.)

8. Claim 14

Claim 14 depends from claim 12, which depends from claim 1, and recites "*wherein the pressure sensing element is used to determine a differential pressure.*"

As previously discussed in Section X.A.7 immediately above, it would have also been obvious to a POSITA to use both sensors along the inner cannula 20 and

the fluid columns within the multilumen catheter 428 proximate Aboul-Hosn's intravascular blood pump to measure the pressure differential between the inlet and outlets of the pump. (Collins ¶¶398-402.) As disclosed by Siess, “[i]nformation relating to the inlet and outlet pressure” of the intravascular blood pump “provides a wealth of information relevant to the function of the pump device,” including the ability “to discern the position of the pump relative to the external sealing member such as the heart valve” to ensure that the pump is properly placed, and the ability to “identify blockage conditions as well as cavitation.” (EX1005[Siess] 11:42-56, 12:8-20.)

Thus, Aboul-Hosn in view of Siess discloses this limitation. (Collins ¶403.)

9. Claim 15

Claim 15 depends from claim 1 and recites “*wherein the intravascular blood pump system further comprising a rotor shroud, a portion of the rotor shroud having an outer diameter matching an inner diameter of a proximal portion of the cannula.*”

Aboul Hosn's pump 50 includes a housing body 52 that houses the rotor 70. (Collins ¶¶405-07; EX1004 [Aboul-Hosn] 12:12-14, 12:31-131:1, 13:7-15.)

Aboul-Hosn further discloses that “[t]he housing body 52 illustrated in this embodiment of the present invention is generally cylindrical-shaped and includes a longitudinally and concentrically aligned inlet tube 55” where “[a] rotor 70 may be

disposed longitudinally inside the inlet tube 55 as shown in FIG. 2.” (EX1004

[Aboul-Hosn] 13:7-15.)




FIG. -2

(Collins ¶408; EX1004 [Aboul-Hosn] FIG. 2, annotated.)

Aboul-Hosn requires “[a] clearance between the inlet tube 55 profile and the rotor 70 should exist to permit the rotor 70 to rotate without contacting the walls of the inlet tube 55.” (*Id.* 15:26-16:1.) Thus, the inlet tube 55 forms the “rotor shroud.” (Collins ¶407.) Moreover, the housing body 52 and the housing cap 60

further may form a unitary body such that the inlet neck 62 and inlet tube 55 together forms the “rotor shroud.” (*Id.*; EX1004 [Aboul-Hosn] 13:3-4.) As shown above in FIG. 2 of Aboul-Hosn, the proximal end of the cannula 20 is coupled to the inlet neck 62. (EX1004 [Aboul-Hosn] 13:24-25.) As such, where the inlet neck 62 and inlet tube 55 together form the “rotor shroud,” an outer diameter of the “rotor shroud” matches the inner diameter of the cannula 20 at its proximal end where it couples to the inlet neck 62. (Collins ¶408.)

Thus, Aboul-Hosn discloses this limitation. (*Id.* ¶409.)

B. Ground II: Claims 7-9, and 11-15 are over Aboul-Hosn in view of Yock, and further in view of Siess and Wampler

1. Claim 1 (Claims 7-9 and 11-15 depend from Claim 1)

a) See element 1(a) – 1(g), Sections X.A.1(a)-(g), above.

Elements 1(a) – 1(g) are the same as in Ground I and rely on Aboul-Hosn.


b) See element 1(h), Section X.A.1(h), above.

This element corresponds to Element 1(h) addressed above for Ground I (see X.A.1(h)), but for this Ground III, Petitioner relies on Yock as explained below.

Again, the '437 patent does not specify what it means to be an *elongate* lumen, much less an elongate lumen *associated with* the cannula. (Collins ¶417.) Notwithstanding, Aboul-Hosn in view of Yock, discloses the “elongate lumen associated with the cannula” as recited by this limitation in the same manner as the '437 patent. (*Id.*)

Aboul-Hosn suggests delivering the intravascular blood pump using the preferred rapid-exchange mechanism. (Collins ¶¶418-23; EX1004[Aboul-Hosn] 11:24-26; EX1006[Yock] 1:15-25; EX1023[Faxon] 59.)

Yock discloses a conventional rapid-exchange mechanism in connection with a minimally invasive device for angioplasty. (Collins ¶424; EX1006[Yock] 7:64-8:25.) As shown below in FIG. 10, the orientation of the sleeve along the side of the tubular member allows for the rapid exchange of the catheter. (Collins ¶428-29; EX1006[Yock] 2:31-37.)



(Collins ¶428; EX1006[Yock] FIG. 10, annotated.)

Yock's tubular member is similar to Aboul-Hosn's cannula as both are polymer tubes that are delivered by catheterization techniques into the patient's vasculature. (Collins ¶¶425-27.) It would have been obvious to a POSITA to apply Yock's conventional sleeve and guide wire rapid-exchange configuration to Aboul-Hosn's cannula (shown below in FIG. 1) to guide the intravascular blood pump using the preferred rapid-exchange technique. (Collins ¶431.)





FIG. - 1

(Collins ¶431.)

A POSTIA would readily understand that lumens within Aboul-Hosn's cannula would also be used for delivering the guidewire using the rapid-exchange technique. (Collins ¶432.) In fact, Yock expressly discloses that the sleeve 66 of FIG. 10 "can be formed integral with the flexible tubular member 62." (EX1006[Yock] 7:68-7:2.) Yock shows an example of such an embedded sleeve in FIG. 8, reproduced below. (Collins ¶433; EX1006[Yock] 6:59-63.)



(Collins ¶433; EX1006[Yock] FIG. 8B, annotated.)

As shown above, the embedded sleeve of Yock is structurally similar to the side lumens within Aboul-Hosn's cannula (i.e. a passageway within the cannula wall running parallel to the central cannula lumen). (Collins ¶434.) As a result, a POSITA would readily appreciate that Aboul-Hosn's cannula can be similarly configured to include an embedded sleeve for a guide wire as in Yock. (*Id.*) Further, a POSITA would also readily understand that the existing side lumens of Aboul-Hosn's cannula can also be used for delivering the guidewire just as well as an embedded sleeve given their similar structures, and as such, would provide a

natural and obvious choice for an embedded rapid-exchange system. (*Id.* ¶¶434-35.)

In the embedded rapid-exchange configuration, the guide wire extends proximally along the cannula and enters a side lumen (either an embedded sleeve or a preexisting passageway) in the wall of the cannula through an opening (such as a port 187 formed in the sidewall of the cannula), and exits the side lumen through its distal end. (*Id.* ¶¶435-36.)




FIG. -23

(Collins ¶436; EX1004[Aboul-Hosn] FIG. 23, annotated.)

As of the EPD, it was well-known to POSITAs that conventional catheterization techniques used for angioplasty devices (such as in Yock) were applicable to intravascular blood pumps (such as Aboul-Hosn's) because of the substantial overlap between the fields of angioplasty and intravascular blood pumps. (Collins ¶426; EX1042[Coleman] 34:25-32; EX1023[Faxon] Ch. 7, "Selection of Balloon Catheters and Guidewires" and 18, "Percutaneous Support Techniques.") Moreover, both types of devices were delivered with the same objective of placing the device in the vasculature to apply treatment to the appropriate location. (Collins ¶426.) Indeed, as explained by Dr. Collins, the same approach (i.e. the Seldinger technique) would have been used conventionally by cardiologists to introduce percutaneous devices, including catheters and intravascular blood pumps, within the patient's vasculature. (*Id.* ¶427; U.S. Patent No. 4,692,148 to Kantrowitz et al. (EX1044, "Kantrowitz") at 5:1-15; U.S. Patent No. 4,468,224 to Enzmann et al. (EX1045, "Enzmann") at 2:5-20).

A POSITA would have been motivated to adapt Aboul-Hosn's intravascular blood pump to be delivered using a rapid-exchange technique, such as by applying the sleeve and guide wire technique of Yock, because of known advantages to using rapid-exchange, including a simplified exchange procedure, reduced guide wire length, increased insertion speed, reduced handling during insertion, and additional design flexibility. (Collins ¶¶430-431.)

Thus, a POSITA would have found it natural, and would have been motivated to configure the cannula of Aboul-Hosn's intravascular blood pump with Yock's conventional sleeve and guide wire rapid-exchange elements (either by forming a sleeve along the outside of the cannula, embedding the sleeve within the sidewall of the cannula, or using a preexisting side lumen within the cannula wall) as doing so would have been merely an application of a known technique, in a conventional manner, to achieve a predictable result. (*Id.* ¶¶431-432.)

In any of the rapid-exchange configurations, the elongate lumen (i.e. a sleeve along the outside of the cannula, an embedded sleeve within the sidewall of the cannula, or a preexisting side lumen within the cannula wall) is associated with the cannula (i.e. the sleeve is associated with the cannula where it is formed along the side of the cannula, and the embedded sleeve and preexisting side lumens are associated with the cannula as they are formed in the sidewall of the cannula). (Collins ¶¶431-432; EX1006[Yock] FIG. 10, 7:68-8:2; EX1004[Aboul-Hosn] 11:24-26, 28:7-12.) Moreover, the sleeve lumen and side lumen of the cannula are dimensioned such that the guide wire passes slideably and coaxially through. (Collins ¶435.) Thus, Aboul-Hosn in view of Yock discloses this limitation. (*Id.* ¶437.)

- c) See element 1(i), Section X.A.1(i), above.

Aboul-Hosn in view of Yock discloses this limitation. (*Id.* ¶¶438-41) When using the preferred rapid-exchange technique, the elongate lumen may either be a sleeve along the outside of the cannula, an embedded sleeve within the sidewall of the cannula, or a preexisting side lumen within the cannula wall, all of which have smaller cross-sections than the cannula lumen. (*Id.*) With respect to the sleeve lumen, as Dr. Collins shows below by attaching the sleeve in FIG. 10 of Yock to the cannula in FIG. 1 of Aboul-Hosn, the sleeve lumen has a cross-section that is smaller than a cross-section of the cannula. (*Id.* ¶439.)







FIG. - 1

(Collins ¶439.)

Moreover, with respect to the side lumens within the cannula, these lumens must have a smaller cross section than the cannula lumen as they are formed within the sidewall of the cannula itself, as shown below in FIG. 8B of Yock and Fig. 20 of Aboul-Hosn. (Collins ¶440.)



(Collins ¶440; EX1006[Yock] FIG. 8B, annotated (top); EX1004[Aboul-Hosn]

FIG. 20, annotated (bottom).)

Accordingly, Aboul-Hosn in view of Yock discloses this limitation. (Collins

¶442.)

d) See element 1(j), Section X.A.1(j), above. “

This limitation is a characteristic feature of a rapid-exchange guide mechanism applied intravascular blood pumps. (Collins ¶443.) As previously discussed in Section X.C.1(b), Aboul-Hosn in view of Yock discloses the intravascular blood pump can be placed using the rapid-exchange technique, and as such, discloses this limitation. (*Id.* ¶444.) As Dr. Collins shows below in FIG. 1 of Aboul-Hosn, where the sleeve lumen of Yock (shown in FIG. 10) is attached to the cannula 27 and is used to pass the guide wire, the elongate lumen (i.e. sleeve lumen) does not extend through the rotor hub because the elongate lumen is attached to the distal end of the cannula of the intravascular blood pump. (*Id.* ¶445.) The cannula lumen also does not extend through the rotor hub because the cannula is coupled to the rotor housing, and as such, the cannula lumen does not extend through the rotor hub within the rotor housing. (*Id.* ¶447.)




FIG. - 1

(Collins ¶445.)

As shown above, the guide wire extends proximally away from the intravascular blood pump without passing through the rotor hub or the catheter coupled to the proximal end of the pump. (*Id.*) This is also the case where the side lumens of the cannula are used to pass the guide wire as shown in FIG. 23 of Aboul-Hosn, reproduced below. (*Id.* ¶448.)




FIG. -23

(Collins ¶448; EX1004[Aboul-Hosn] FIG. 23, annotated.)


e) See element 1(k), Section X.A.1(k), above.

Element 1(k) is the same as in Ground I and relies on Aboul-Hosn.

f) See element 1(l), Section X.A.1(l), above.

Yock in combination with Aboul-Hosn discloses this limitation. (Collins ¶451.) As previously discussed in Section X.C.1(b), Aboul-Hosn's intravascular blood pump can be delivered with the rapid-exchange technique by using a sleeve lumen (such as Yock's) attached along the side of the cannula or using an

embedded sleeve lumen or preexisting passageway (i.e. side lumens) within the sidewall of the cannula, any of which can be the “elongate lumen” and receive a guide wire passing through it. (*Id.* ¶¶454-56.) Where the sleeve lumen attached to the side of the cannula is used, as shown in annotated FIG. 10 of Yock below, the guide wire enters the intravascular blood pump system through one end of the elongate lumen, and exits through an opposite (distal) end. (*Id.* 452; EX1006[Yock] 8:10-16.)



(Collins ¶452; EX1006[Yock] FIG. 10, annotated).

This is also the case where the side lumens within Aboul-Hosn’s cannula are used, as shown in FIG. 23 of Aboul-Hosn below. (Collins ¶458.)




FIG. -23

(Collins ¶454; EX1004[Aboul-Hosn] FIG. 23, annotated.)

In either configuration, as shown above in FIG. 10 of Yock and FIG. 23 of Aboul-Hosn, the elongate lumen does not pass through the rotor hub or the catheter coupled to the proximal end of the pump, and the guide wire extends in a distal direction away from the pump. (Collins ¶¶455-56; EX1006[Yock] FIG. 10; EX1004[Aboul-Hosn] FIG. 20.)

Thus, Aboul-Hosn in view of Yock, discloses this limitation. (*Id.* ¶457.)


g) See element 1(m) – 1(p), Sections X.A.1(m)-(p), above.

Elements 1(m) – 1(p) are the same as in Ground I and rely on Aboul-Hosn (and Siess for certain limitations).

2. Claim 7

Claim 7 depends from claim 1 and recites “*further comprising the step of inserting a guide catheter into the patient, wherein the guide wire is placed in the patient through the guide catheter.*”

As previously explained in Parts V.B.3, the use of a guide-catheter to place a guide wire was a well-known technique. (Collins ¶463.) Yock is one such example, where the cardiac assist devices are advanced to the desired location by first using a conventional guiding catheter. (*Id.*; EX1006[Yock] 3:56-50; FIG. 1.) Yock’s FIG. 1 shows the guide wire 27 (red) with a flexible tip 28 extending through the guiding catheter 17 (blue) that can be used to position a balloon 33 (green) at a desired location.



(Collins ¶463; EX1006[Yock] FIG. 1, annotated)

Prior to placing the guidewire, Yock describes that “[t]he guiding catheter 17 is inserted into the coronary artery in a conventional manner.” (See Collins

¶464; EX1006[Yock] 3:56-57.) Subsequently, the guide wire 27 is advanced into the guiding catheter 17. (*Id.* 4:25-28.) Similar to Aboul-Hosn, Yock also discloses that “[t]he position of the guide wire 27 in the desired arterial vessel can be observed under a fluoroscope by using x-ray techniques well known to those skilled in the art.” (Collins ¶464; EX1006 [Yock] at 4:37-40.) After placement of the guide wire 27 in the “desired arterial vessel,” the dilation balloon 33 can be advanced over the guide wire 27 to the desired location. (*Id.* 4:46-50.)

It would have been routine for a POSITA to apply Yock’s guiding catheter technique to help place the Aboul-Hosn’s guide wire. (Collins ¶465.) Both Aboul-Hosn and Yock use imaging techniques to place a guide wire at a desired location. (*Id.*; EX1004 [Aboul-Hosn] at 22:10-12; EX1006 [Yock] at 4:25-28.) Yock further discloses that, in conjunction with imaging techniques, a “conventional guiding catheter” 17 can be used help place the guide wire 27 to the desired location because with the use of the guiding catheter 17 “greater pushability can be obtained” when navigating the patient’s vasculature. (*Id.* 4:60-66.) Thus, using a guiding catheter as taught by Yock to help guide Aboul-Hosn’s guide wire would have been nothing more than the application of a known technique to achieve predictable results – i.e. “greater pushability” of Aboul-Hosn’s guide wire. (Collins ¶465.) A POSITA would thus have been motivated to use Yock’s conventional guiding catheter technique to help guide Aboul-Hosn’s guide wire to

a desired location within the patient's vasculature before advancing Aboul-Hosn's intravascular blood pump system using the guide wire in a rapid-exchange configuration. (*Id.*)

Thus, Aboul-Hosn in view of Yock discloses this limitation. (Collins. ¶466.)

3. Claims 8, 9, 11-15

Grounds for these claims are identical to Ground I and rely on Aboul-Hosn (and Wampler or Siess for certain limitations). *See* Sections X.A.3-9.

XI. CONCLUSION

Based on the foregoing, claims 7-9, 11-15 of the '437 patent recite subject matter that is unpatentable. The Petitioner requests institution of an IPR to cancel these claims.

Respectfully Submitted,

/David M. Tennant/

David M. Tennant
Registration No. 48,362

Table of Exhibits for U.S. Patent 9,597,437 Petition for *Inter Partes* Review

Exhibit	Description
1001	U.S. Patent No. 9,597,437 (“’437 patent”)
1002	Collins Declaration (“Collins”)
1003	File History of U.S. Patent No. 9,597,437 (“’437 PH”)
1004	WO 99/02204 (“Aboul-Hosn”)
1005	U.S. Patent No. 5,921,913 (“Siess”)
1006	U.S. Patent No. 5,061,273 (“Yock”)
1007	Wampler et al., <i>Clinical Experience with the Hemopump Left Ventricular Support Device</i> , published in <i>Supported Complex and High Risk Coronary Angioplasty</i> , ch. 14, 231-49 (Springer 1 st ed. 1991) (“Wampler”)
1008	U.S. Patent No. 4,625,712 (“Wampler ’712”)
1009	U.S. Patent No. 4,846,152 (“Wampler ’152”)
1010	U.S. Patent No. 4,479,497 (“Fogarty”)
1011	U.S. Patent No. 6,248,091 (“Voelker”)
1012	U.S. Provisional Patent Appln. 60/152,249 (“’249 provisional application”)
1013	E.P. Publication No. 0916359 (“Siess ’359”)
1014	E.P. Publication No. 0157859 (“Moise”)
1015	U.S. Patent No. 3,879,516 (“Wolvek”)
1016	U.S. Patent No. 4,764,324 (“Burnham”)
1017	U.S. Patent No. 4,944,745 (“Sogard”)

1018	U.S. Patent No. 6,544,216 (“Sammler”)
1019	U.S. Patent No. 6,176,822 (“Nix”)
1020	U.S. Patent No. 6,849,068 (“Bagaoisan”)
1021	<i>Diastolic Balloon Pumping (With Carbon Dioxide) in the Aorta – a Mechanical Assistance to the Failing Circulation</i> by S.D. Mouloupoulos (1962) (“Mouloupoulos”)
1022	Pierce, W. S. et al., <i>Portable artificial heart systems</i> , ASAIO Journal 29.1: 757-59 (Apr. 1983) (“Pierce”)
1023	<i>Practical Angioplasty</i> (David P. Faxon, M.D. ed., Raven Press 1993) (“Faxon”)
1024	Abou-Awdi N.L., et al., <i>Hemopump Left Ventricular Support in the Peripartum Cardiomyopathy Patient</i> , 8 J. Cardiovascular Nursing, Issue 2 (Jan. 1994) (“Abou-Awdi”)
1025	Lynn R. Williams, <i>Reference Values for Total Blood Volume and Cardiac Output in Humans</i> , Oak Ridge Nat’l Lab. (Sept. 1994) (“Williams”)
1026	E.E. Kunst, J.A. van Alste, T. Arts, and H. B. K. Boom, <i>Integrated Unit for Programmable Control of the 21F Hemopump and Registration of Physiological Signals</i> , Med. & Biol. Eng. & Comput. 694-95 (Nov. 1994) (“Kunst”)
1027	Konishi, H. et al., <i>Controller for an Axial Flow Blood Pump</i> , Artificial Organs 20(6): 618–20 (Jun. 1996) (“Konishi”)
1028	<i>Textbook of Medical Physiology</i> by Arthur C. Guyton and John E. Hall, 9th Edition (1996) (“Guyton”)
1029	Lawrence K. Altman, <i>A Tiny Heart Pump Saves Its First Life</i> , <i>Researchers Report</i> , N.Y. Times, May 5, 1988.
1030	Andre F. Cournand et al, <u>Nobel Prize in Physiology or Medicine</u> 1956, Nobel Prize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/ (last visited Jan. 25, 2017)

1031	Andre F. Cournand, <i>Control of the pulmonary circulation in man with some remarks on methodology</i> , Nobel Lecture, December 11, 1956, page 531 and page 533.
1032	Frank K. White. <i>Fluid Mechanics</i> , 2 nd edition, 1986. (“White”)
1033	O. Jegaden, “Clinical results of Hemopump support in surgical cases,” 1991. (“Jegaden”)
1034	Declaration of Pamela Stransbury
1035	Declaration of Kiersten Batzli
1036	Library of Congress, Catalog Record of <i>Supported Complex and High Risk Coronary Angioplasty</i> , ch. 14, 231-49 (Springer 1 st ed. 1991)
1037	Library of Congress, Catalog Record of Mouloupoulos et. al, “Diastolic Balloon Pumping (With Carbon Dioxide) in the Aorta – a Mechanical Assistance to the Failing Circulation,” in the <i>American Heart Journal</i> , vol. 63, no. 1 (1962) 669-675
1038	Library of Congress, Catalog Record of Konishi et al., “Controller for an axial flow blood pump,” in <i>Artificial Organs Journal</i> , vol. 20, no. 6 (Jun. 1996) 618-620
1039	Library of Congress, Catalog Record of <i>Textbook of Medical Physiology</i> by Arthur C. Guyton and John E. Hall, 9th edition (1996)
1040	Library of Congress, Catalog Record of <i>Fluid Mechanics</i> , 2 nd edition, ed. Frank M. White (1986)
1041	ZB Med, Catalog Record of <i>Temporary Cardiac Assist with an Axial Pump</i> , ed. W. Flaming (1991)
1042	U.S. Patent No. 5,928,181 (“Coleman”)
1043	File History of U.S. Patent No. 8,888,728 (“728 PH”)
1044	U.S. Patent No. 4,692,148 (“Kantrowitz”)
1045	U.S. Patent No. 4,468,224 (“Enzmann”)
1046	Declaration of Susanne Leupold and accompanying Exhibits Regarding O. Jegaden
1047	U.S. Patent No. 4,135,253 (“Reich”)
1048	R.W. Smalling, <i>The use of mechanical assist devices in the management of cardiogenic shock</i> , <i>Texas Heart Institute Journal</i> , vol. 18, NO. 4, 1991, pp 275-281.
1049	U.S. Patent No. 5,421,338 (“Crowley”)

CERTIFICATE OF WORD COUNT UNDER 37 CFR § 42.24(d)

Pursuant to 37 C.F.R. §§ 42.24(d) and 42.24(a)(1), I hereby certify that the number of words in this Petition is 13,352 words excluding the table of contents, table of authorities, mandatory notices under §42.8, certificate of service, certificate of word count, and the listing of exhibits.

Respectfully Submitted,

/David M. Tennant/

David M. Tennant
Lead Counsel
Registration No. 48,362

CERTIFICATE OF SERVICE

I, Daniel Shults, hereby certify that I am a resident of the State of Maryland and over the age of eighteen years, and not a party to the within action; my business address is 701 13th Street NW, #600, Washington, DC, 20005. On April 18, 2017, I caused the within documents:

- Petition for Inter Partes Review of U.S. Patent No. 9,975,437 Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104
- List of Exhibits for Petition for Inter Partes Review of U.S. Patent No. 9,975,437 (EX1001-1049)
- Exhibits 1001-1049
- Power of Attorney

to be served via FedEx on the attorney of record with the following correspondence address as listed on PAIR:

Getinge US Legal Shared Services
1300 MacArthur Boulevard
Mahwah NJ 07430

and to be served via FedEx on the designated representative of patent owner with the following correspondence address:

Alston & Bird LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000

I declare that I am employed in the office the above captioned attorney at whose direction the service was made.

/s/Daniel Shults
Daniel Shults